NCT05364190

Canagliflozin in Patients With Acute Decompansted Heart Failure

Efficacy and Safety of Early Initiation of Canagliflozin in Patients With Acute Decompansted Heart Failure

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 142 (actual)
• Sponsor: October 6 University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The study aims to investigate the efficacy and safety of the early initiation of canagliflozin treatment in hospitalized heart failure patients with volume overload (warm-wet) who require the use of I.V loop diuretic during the hospitalization period.

Detailed description

The study will focus on the role of adding canagliflozin to I.V loop diuretic therapy early in unstable hospitalized acute heart failure patients regardless of diabetic state, patients who will be included in the study will continue on canagliflozin for 3 months after hospital discharge to evaluate the incidence of re-hospitalization, mortality rate and other benefits related to HF symptoms will be investigated.

Conditions

• Chronic Heart Failure
• Acute Heart Failure
• Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Canagliflozin	Canagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
DRUG	Empagliflozin	Empagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.

Timeline

• Start date: 2022-06-04
• Primary completion: 2023-12-01
• Completion: 2024-03-01
• First posted: 2022-05-06
• Last updated: 2024-07-11

Locations

1 site across 1 country: Egypt